Overview

A Multicenter, Open-label, Non-randomized Phase I/IIa Clinical Trial to Evaluate INR102 Injection in Patients With Prostate Cancer

Status:
NOT_YET_RECRUITING
Trial end date:
2029-10-22
Target enrollment:
Participant gender:
Summary
A Phase I/IIa clinical trial to evaluate the safety, tolerability, pharmacokinetics, radiation dosimetry, and preliminary efficacy of INR102 injection in patients with prostate cancer.
Phase:
PHASE1
Details
Lead Sponsor:
Yunhe Pharmaceutical (Tianjin) Co., Ltd